Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
129
resultados
Última actualización
19/05/2024 [06:58:00]
Resumen de: WO2024102901A1
The present disclosure provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R3 and X are defined herein; pharmaceutical compositions; dosage forms comprising the compounds or pharmaceutical compositions, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, or treating sepsis in a subject in need thereof, comprising administering the compounds, pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof.
Resumen de: US2024159772A1
Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
Resumen de: US2024158485A1
The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.
Resumen de: US2024159763A1
The disclosure provides methods and materials for detecting endogenous IgA antibodies to one or more, or all, of OmpC (ACA), Ki67 (AKiA), TK1, integrin (AINTA) and keratin (AKERA), which are useful to diagnose and distinguish chronic enteropathies, e.g. gastrointestinal neoplasms, e.g., gastrointestinal lymphoma, and, inflammatory conditions, e g inflammatory bowel disease, in felines.
Resumen de: WO2024094817A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Resumen de: WO2024096121A1
The present disclosure provides a bacterial preparation that can be used to treat inflammatory bowel disease. More specifically, the present disclosure relates to a microorganism in which a gene from at least one of a fimbria operon gene group, a pilus-associated gene group, and a two-component regulatory system gene group has been modified. The modification suppresses inflammation in a host compared to microorganisms in which the gene is unmodified.
Resumen de: US2020368291A1
An object of the present invention is to provide a cell population comprising safe adherent stem cells maintaining a normal karyotype and a method for producing the cell population, and a pharmaceutical composition comprising the cell population. According to the present invention, a production method of a cell population comprising adherent stem cells, comprising obtaining a cell population in which the proportion of KCNAB1-positive adherent stem cells in the cell population is 85% or more, is provided.
Resumen de: US2024150453A1
The subject matter disclosed herein is generally directed to stratifying and treating inflammatory diseases. In particular, the present invention provides for detecting treatment naive cell states that predict the response of a subject having inflammatory bowel disease to anti-TNF-blockade. The cells are T cells, NK cells, innate lymphoid cells, myeloid and/or epithelial cell subsets defined by their gene expression as determined by single cell RNA sequencing. Alternatively, the responders are identified by gene expression in a sample.
Resumen de: WO2024086955A1
The present invention relates to a method for obtaining a circulating mitochondria-enriched composition, avoiding platelet activation. This method obtains a circulating mitochondria-enriched composition comprising a high concentration of circulating mitochondria and at the same time comprising a low concentration of positive mitochondria for the CD42b, CD42A and/or CD41 markers. This composition is used to prepare a drug useful for counteracting CD4+ T lymphocyte hyperactivation. These CD4+ T lymphocytes are hyperactive in acute inflammatory processes or in autoimmune diseases. These autoimmune diseases include: Systemic Lupus Erythematosus (SLE); Rheumatoid arthritis; Psoriasis; Antiphospholipid syndrome; Multiple sclerosis; Atherosclerosis; Osteoarthritis; Type I diabetes; Sjögren's syndrome; Myasthenia gravis; Crohn's disease; Ulcerative colitis; Vasculitis; Vasculitis associated with anti-neutrophil cytoplasmic antibodies; Graft-versus-host disease; Preeclampsia and/or Celiac disease.
Resumen de: CN116183929A
Contemplated kits and methods for food sensitivity are based on reasonable selection of food preparations with established discriminant p values. Particularly preferred kits include kits with a minimum number of food preparations having an average discriminant p value of < = 0.07, determined from their original p values, or an average discriminant p value of < = 0.10, determined from FDR multiple corrected p values. In further contemplated aspects, the compositions and methods for food sensitivity are also stratified by gender to further enhance predictive values.
Resumen de: WO2024085698A1
The present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a glycogen phosphorylase (PYGL) inhibitor as an active ingredient, and a method for screening for a material for the prevention or treatment of inflammatory bowel disease. By using the pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a PYGL inhibitor as an active ingredient, according to the present invention, inflammatory bowel disease such as ulcerative colitis can be prevented or treated. Also, through the method for screening for a material for the prevention or treatment of inflammatory bowel disease, according to the present invention, a material that reduces PYGL activity can be determined as a candidate material for the prevention or treatment of inflammatory bowel disease.
Resumen de: WO2024085698A1
The present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a glycogen phosphorylase (PYGL) inhibitor as an active ingredient, and a method for screening for a material for the prevention or treatment of inflammatory bowel disease. By using the pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a PYGL inhibitor as an active ingredient, according to the present invention, inflammatory bowel disease such as ulcerative colitis can be prevented or treated. Also, through the method for screening for a material for the prevention or treatment of inflammatory bowel disease, according to the present invention, a material that reduces PYGL activity can be determined as a candidate material for the prevention or treatment of inflammatory bowel disease.
Resumen de: WO2024085195A1
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin αvβ6 in a specimen.
Resumen de: WO2024086683A2
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of Lachnospiraceae flagellin peptides, which can be selected from a hinge region of Lachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.
Resumen de: US2024122995A1
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.
Resumen de: AU2022289038A1
Provided herein are methods for diagnosing functional gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome, comprising detecting IgG antibodies in a sample obtained from a subject, wherein the IgG antibodies recognise one or more antigens from Streptococcus salivarius. Also provided are kits for detecting IgG antibodies for use in the diagnosis of functional gastrointestinal disorders, and methods for selecting subjects for treatment for functional gastrointestinal disorders.
Resumen de: WO2024076967A1
The present invention provides compositions and methods for reducing the level and/or activity of a TET protein, for treating or preventing a disease and disorder associated with an increased level and/or activity of a TET protein, for reducing, stopping, or reversing weight loss, for inducing apoptosis in disease-associated macrophage (e.g., endometriosis-associated macrophage and tumor-associated macrophage) and/or cancer-associated fibroblast, and/or for preventing or treating various diseases or disorder (e.g., endometriosis, non-alcoholic steatohepatitis, inflammatory disease or disorder, chronic inflammatory disease or disorder, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, cancer, and/or cancer- associated diseases or disorders). In various embodiments, the method comprises administering a degrader of TET protein, inhibitor of TET protein, or a combination thereof as a therapeutic.
Resumen de: US2024094224A1
Proxies for physiological states of tissue are provided. Accordingly, there are provided methods of determining host AMP landscape, establishing a profile indicative of tissue status, and identifying proxies for tissue status in AMP profiles of samples of secretions, exudates and/or excretions of the tissue. Also provided are methods for determination of disease severity and chronology.
Resumen de: CA3219846A1
The present disclosure is generally relates to methods of treating and diagnosing ulcerative colitis. The methods are particularly suitable for treating and diagnosing a specific sub-group of patients with ulcerative colitis. The methods are also particularly suitable for treating and diagnosing urgency in a patient having or suspected of having ulcerative colitis. The methods are also particularly suitable for treating and diagnosing stool frequency and bowel urgency in a patient having or suspected of having ulcerative colitis.
Resumen de: US2024103008A1
The present disclosure provides matched gut and peripheral biomarkers to assess, identify and improve therapeutic measures for IBD, in particular ulcerative colitis and Crohn's disease.
Resumen de: WO2024061978A1
The invention relates to a method for the diagnosis of ulcerative colitis in a subject by detecting a nucleic acid target region and to oligonucleotides, oligonucleotide probes and kits to be used in this method.
Resumen de: US2024101715A1
Provided are various embodiments relating to caninized TNFα antibodies and caninized NGF antibodies. Such antibodies can be used in methods to treat canines with inflammatory conditions, such as inflammatory bowel disease and/or in methods to treat canines with pain, such as osteoarthrititic pain, back pain, cancer pain, and/or a neuropathic pain.
Resumen de: CN117120826A
The present disclosure provides methods for monitoring mucosal healing in a patient suffering from a digestive disease or for use in pre-disease states and including intestinal and parenteral disorders in which digestive tract permeability is increased. The method may include establishing a baseline of the patient, treating a digestive disease or a pre-disease state of the patient, measuring digestive tract permeability of the patient after treatment, and comparing a second total percentage of the recovered administered doses to the baseline total percentage of the recovered administered doses.
Resumen de: EP4343001A1
The invention relates to a method for the diagnosis of ulcerative colitis in a subject by detecting a nucleic acid target region and to oligonucleotides, oligonucleotide probes and kits to be used in this method.
Nº publicación: CN117741141A 22/03/2024
Solicitante:
TIANJIN HOSPITAL OF ITCWM NANKAI HOSPITAL
\u5929\u6D25\u5E02\u4E2D\u897F\u533B\u7ED3\u5408\u533B\u9662\uFF08\u5929\u6D25\u5E02\u5357\u5F00\u533B\u9662\uFF09
Resumen de: CN117741141A
The invention relates to the technical field of biological medicine, in particular to a system for judging DSS-induced ulcerative colitis based on peripheral blood T cell subsets and application of the system, and the system comprises a sample collecting and processing module which is set to obtain peripheral blood mononuclear cells; the detection module is set to identify and count the total number of CD45 + CD3 + T cells in the peripheral blood mononuclear cells obtained by the sample collecting and processing module, and divide and respectively count the cell numbers of the following cell subgroups: Th1, Th2, Th17, CD 8 + NK1. 1 + gamma delta T, CD62L + CD8 + T and NK1. 1 + CD8 + T to obtain the proportion of each cell subgroup; the prediction and judgment module is set to realize the following judgment: comparing the proportions of the cell subgroups with corresponding reference values respectively, and when the proportions of the Th2, Th17 and CD8 + NK1. 1 + gamma delta T cell subgroups are higher than the reference values; if the proportion of the cell subsets NK1, Th1, CD62L + CD8 + T and NK1. 1 + CD8 + T is lower than a reference value, the DSS-induced ulcerative colitis is prompted.
BOPI
Sede Electrónica
